{"id":51915,"date":"2024-07-08T19:29:34","date_gmt":"2024-07-08T18:29:34","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=51915"},"modified":"2024-10-15T19:41:03","modified_gmt":"2024-10-15T18:41:03","slug":"defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/","title":{"rendered":"Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX)"},"content":{"rendered":"<h2>Defence Therapeutics receives a no-objection letter from Health Canada for a Phase I Trial of ACCUM-002 (AccuTOX) as an anti-cancer molecule in patients with melanoma.<\/h2>\n<p>Defence Therapeutics Inc, a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that it received a No Objection Letter (\u201cNOL\u201d) from Health Canada for its Clinical Trial Study number ACCUM-002-01 entitled \u201cA Phase I trial of Intratumoral Administration of ACCUM-002TM as a Monotherapy and in Combination with Opdualag in Patients with Unresectables, Stage IIIB and IV, Melanoma\u201d.<\/p>\n<p>The primary objectives of this study are to determine the safety and tolerability of intratumoral administration of AccuTOX\u00ae, as a monotherapy and in combination with Opdualag which combines the LAG-3 checkpoint inhibitor relatlimab and PD-1 inhibitor nivolumab. The secondary objectives are to obtain preliminary efficacy data and to determine the Maximum Tolerated Dose (\u201cMTD\u201d) and recommended Phase 2 Dose (\u201cRP2D\u201d) of AccuTOX\u00ae exploits as an immune booster and anti-cancer molecule.<\/p>\n<p><a href=\"https:\/\/www.biospace.com\/article\/releases\/cancer-immunotherapy-market-size-to-increase-usd-280-11-bn-by-2033\/\" target=\"_blank\" rel=\"noopener\">According to Vision Research Reports, the global cancer immunotherapy market size was estimated at USD 125.73 billion in 2023 and it is projected to increase USD 280.11 billion by 2033 with a CAGR of 8.34% from 2024 to 2033.<\/a><\/p>\n<p>The Defence team is already preparing Phase I in Canada, most likely to be conducted in Quebec and Ontario. The hospital\u2019s sites will be confirmed upon agreement finalisation.<\/p>\n<p>\u201cAccuTOX\u00ae is Defence\u2019s flagship asset in the anti-cancer therapeutics field and this Phase I clinical trial shall demonstrate and confirm primarily its safety and secondly its potency. We are thrilled to getting ready for this Phase I in Canada. Defence remains committed to its mission of addressing unmet clinical needs and in pursuing its goals to become a global leader in the development of innovative anti-cancer therapies,\u201d said Sebastien Plouffe, Chief Executive Officer of Defence Therapeutics.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Defence Therapeutics receives a no-objection letter from Health Canada for a Phase I Trial of ACCUM-002 (AccuTOX) as an anti-cancer molecule in patients with melanoma. Defence Therapeutics Inc, a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that it received a No Objection Letter (\u201cNOL\u201d) from Health Canada [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":51911,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[23535],"tags":[24628],"acf":[],"yoast_head":"\n<title>Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX) | Innovation News Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX)\" \/>\n<meta property=\"og:description\" content=\"Defence Therapeutics receives a no-objection letter from Health Canada for a Phase I Trial of ACCUM-002 (AccuTOX) as an anti-cancer molecule in patients with melanoma. Defence Therapeutics Inc, a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that it received a No Objection Letter (\u201cNOL\u201d) from Health Canada [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/\" \/>\n<meta property=\"og:site_name\" content=\"Innovation News Network\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/InnoNewsNetwork\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-08T18:29:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-15T18:41:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-002.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Innovation News Network\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@InnoNewsNetwork\" \/>\n<meta name=\"twitter:site\" content=\"@InnoNewsNetwork\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Innovation News Network\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/\"},\"author\":{\"name\":\"Innovation News Network\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/38f0969540c25d7fff4c7accd510863e\"},\"headline\":\"Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX)\",\"datePublished\":\"2024-07-08T18:29:34+00:00\",\"dateModified\":\"2024-10-15T18:41:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/\"},\"wordCount\":314,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-002.jpg\",\"keywords\":[\"PP Defence Therapeutics\"],\"articleSection\":[\"Partner News\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/\",\"name\":\"Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX) | Innovation News Network\",\"isPartOf\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-002.jpg\",\"datePublished\":\"2024-07-08T18:29:34+00:00\",\"dateModified\":\"2024-10-15T18:41:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#primaryimage\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-002.jpg\",\"contentUrl\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-002.jpg\",\"width\":1920,\"height\":1080,\"caption\":\"Defence Therapeutics receives no objection letter from Health Canada for Phase I Trial of ACCUM-002 (AccuTOX)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.innovationnewsnetwork.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#website\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/\",\"name\":\"Innovation News Network\",\"description\":\"Science, Research &amp; Innovation News\",\"publisher\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.innovationnewsnetwork.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#organization\",\"name\":\"Innovation News Network\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2022\/01\/inn-logo-yoast-seo-organisation-1920-1080-001.jpg\",\"contentUrl\":\"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2022\/01\/inn-logo-yoast-seo-organisation-1920-1080-001.jpg\",\"width\":1920,\"height\":1080,\"caption\":\"Innovation News Network\"},\"image\":{\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/InnoNewsNetwork\",\"https:\/\/x.com\/InnoNewsNetwork\",\"https:\/\/www.linkedin.com\/company\/innovation-news-network\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/38f0969540c25d7fff4c7accd510863e\",\"name\":\"Innovation News Network\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/deb82a7db772be9bb29280b33f0291e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/deb82a7db772be9bb29280b33f0291e9?s=96&d=mm&r=g\",\"caption\":\"Innovation News Network\"},\"url\":\"https:\/\/www.innovationnewsnetwork.com\/author\/mattkilgariff\/\"}]}<\/script>\n","yoast_head_json":{"title":"Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX) | Innovation News Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/","og_locale":"en_GB","og_type":"article","og_title":"Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX)","og_description":"Defence Therapeutics receives a no-objection letter from Health Canada for a Phase I Trial of ACCUM-002 (AccuTOX) as an anti-cancer molecule in patients with melanoma. Defence Therapeutics Inc, a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that it received a No Objection Letter (\u201cNOL\u201d) from Health Canada [&hellip;]","og_url":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/","og_site_name":"Innovation News Network","article_publisher":"https:\/\/www.facebook.com\/InnoNewsNetwork","article_published_time":"2024-07-08T18:29:34+00:00","article_modified_time":"2024-10-15T18:41:03+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-002.jpg","type":"image\/jpeg"}],"author":"Innovation News Network","twitter_card":"summary_large_image","twitter_creator":"@InnoNewsNetwork","twitter_site":"@InnoNewsNetwork","twitter_misc":{"Written by":"Innovation News Network","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#article","isPartOf":{"@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/"},"author":{"name":"Innovation News Network","@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/38f0969540c25d7fff4c7accd510863e"},"headline":"Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX)","datePublished":"2024-07-08T18:29:34+00:00","dateModified":"2024-10-15T18:41:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/"},"wordCount":314,"commentCount":0,"publisher":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#organization"},"image":{"@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#primaryimage"},"thumbnailUrl":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-002.jpg","keywords":["PP Defence Therapeutics"],"articleSection":["Partner News"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/","url":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/","name":"Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX) | Innovation News Network","isPartOf":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#primaryimage"},"image":{"@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#primaryimage"},"thumbnailUrl":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-002.jpg","datePublished":"2024-07-08T18:29:34+00:00","dateModified":"2024-10-15T18:41:03+00:00","breadcrumb":{"@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#primaryimage","url":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-002.jpg","contentUrl":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2024\/10\/inn-feature-image-defence-therapeutics-002.jpg","width":1920,"height":1080,"caption":"Defence Therapeutics receives no objection letter from Health Canada for Phase I Trial of ACCUM-002 (AccuTOX)"},{"@type":"BreadcrumbList","@id":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-no-objection-health-canada-trial-accum-002-accutox\/51915\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.innovationnewsnetwork.com\/"},{"@type":"ListItem","position":2,"name":"Defence Therapeutics receives no-objection letter from Health Canada for phase I trial of ACCUM-002 (AccuTOX)"}]},{"@type":"WebSite","@id":"https:\/\/www.innovationnewsnetwork.com\/#website","url":"https:\/\/www.innovationnewsnetwork.com\/","name":"Innovation News Network","description":"Science, Research &amp; Innovation News","publisher":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.innovationnewsnetwork.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.innovationnewsnetwork.com\/#organization","name":"Innovation News Network","url":"https:\/\/www.innovationnewsnetwork.com\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2022\/01\/inn-logo-yoast-seo-organisation-1920-1080-001.jpg","contentUrl":"https:\/\/www.innovationnewsnetwork.com\/wp-content\/uploads\/2022\/01\/inn-logo-yoast-seo-organisation-1920-1080-001.jpg","width":1920,"height":1080,"caption":"Innovation News Network"},"image":{"@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/InnoNewsNetwork","https:\/\/x.com\/InnoNewsNetwork","https:\/\/www.linkedin.com\/company\/innovation-news-network\/"]},{"@type":"Person","@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/38f0969540c25d7fff4c7accd510863e","name":"Innovation News Network","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.innovationnewsnetwork.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/deb82a7db772be9bb29280b33f0291e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/deb82a7db772be9bb29280b33f0291e9?s=96&d=mm&r=g","caption":"Innovation News Network"},"url":"https:\/\/www.innovationnewsnetwork.com\/author\/mattkilgariff\/"}]}},"publishpress_future_action":{"enabled":false,"date":"2025-03-06 00:30:58","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/posts\/51915"}],"collection":[{"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/comments?post=51915"}],"version-history":[{"count":3,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/posts\/51915\/revisions"}],"predecessor-version":[{"id":51925,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/posts\/51915\/revisions\/51925"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/media\/51911"}],"wp:attachment":[{"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/media?parent=51915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/categories?post=51915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.innovationnewsnetwork.com\/wp-json\/wp\/v2\/tags?post=51915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}